Abstract 1571P
Background
Esophageal carcinoma (EC) a high rank common and death cancer. The intricate tumor microenvironment of EC necessitates a better performance signature to distinguish different tumor prognoses, which may facilitate enable appropriate treatment selection for patients. This is the first study aimed to identify the immune and metabolism gene signature for prognosis prediction of EC and constructing a prediction model, from EC transcriptional data.
Methods
Using differential expression analysis to compare the transcriptomic data associated with immune and metabolism from TCGA dataset between 10 normal population and 162 EC patient samples. Screen the differentially expressed genes (DEGs) related to prognosis by univariate Cox regression, the subtype clusters were identified, and the characteristics were analyzed. Through multivariate Cox and LASSO regression, a prediction model of the EC prognostic risk score (RS) was established and validated.
Results
Compared with the normal population, there were 568 immune-related genes of differential expression in EC, with 369 up-regulated and 199 down-regulated; and 810 metabolism-related genes, including 428 up-regulated and 382 down-regulated. Based on these immune and metabolic DEGs, 12 prognosis-related genes identified that could be clustered patients into three subtypes. The prognosis of the three subtypes was significantly different (P= 0.0016). Furthermore, the prediction model of prognostic RS was constructed based on six genes included STC2, APLN, GPER1, FMO1, SNRPB, and FABP3 from above DEGs. The patients with low RS had significantly higher OS (P < 0.001) than those in the high RS group, and it had a certain predictive accuracy (AUC of 5 years OS = 0.818). Those were verified in the GSE53625 cohort.
Conclusions
Immune and metabolism gene were significantly correlated with the prognosis of EC patients, and the prognostic model by six DEGs had good prediction efficiency. These were expected to help clinical diagnosis and therapy, and provides a new perspective to explore the molecular mechanisms of EC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22